The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling
J. Clin. Invest. Michael W.-H. Wang, et al. 114:206 doi:10.1172/JCI15797 [Go to this article.]

Figure 2
Osteoclastogenic arrest by ritonavir is reversible. (A) Osteoclasts were generated from bone marrow macrophages as in Figure 1 and quantitated by TRAP solution assay. The presence of ritonavir (20 μg/ml) completely suppresses osteoclast formation, while normalization of osteoclast number follows withdrawal of the PI on day 3, 4, and 5. + Ritonavir, continuous ritonavir exposure; – Ritonavir, ritonavir withdrawal. (B) TRAP-stained osteoclasts on day 7 of culture following persistent exposure to ritonavir (left panel) and withdrawal of ritonavir on day 5 (right panel). Magnification, ×200.